MLXIPL and metabolic dysfunction-associated steatotic liver disease: We demonstrate that, during NAFLD progression, TRIM21 suppresses hepatic lipogenesis and fructolysis on a transcriptional, RNA splicing and enzymatic level by polyubiquitination and degradation of SREBP1, ChREBP, A1CF, ACC1, and FASN.